The Effect of Esmolol on Clinical Prognosis of Patients With Severe Sepsis
The Effect of Esmolol on Tissue Perfusion and Clinical Prognosis of Patients With Severe Sepsis: a Prospective Cohort Study .
研究概览
详细说明
enrollment:151 patients
Inclusion criteria: (1) age > 18 years; (2) severe sepsis (acute organ dysfunction secondary to infection )diagnosis according to Campaign to Save Septic Patients: 2008 Treatment Guidelines for Severe Sepsis and Septic Shock, who (3) mechanical ventilation via endotracheal intubation with a tidal volume of 6 mL/kg; and (4) satisfactory sedation and analgesic treatment, with HR > 100 bpm.
研究类型
注册 (实际的)
阶段
- 不适用
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- age > 18 years;
- severe sepsis (acute organ dysfunction secondary to infection )diagnosis according to Campaign to Save Septic Patients: 2008 Treatment Guidelines for Severe Sepsis and Septic Shock,
- mechanical ventilation via endotracheal intubation with a tidal volume of 6 mL/kg;
- satisfactory sedation and analgesic treatment, with HR > 100 bpm.
Exclusion Criteria:
- pre-existing cardiac dysfunction, valvular heart disease, high-degree atrioventricular block;
- acute or chronic pulmonary heart disease;
- a history of serious asthma;
- chronic renal insufficiency;
- cancer, autoimmune diseases, or contraindications for placement of deep venous catheter;
- insulin-dependent diabetes.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：非随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：esmolol group
patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava.
|
patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava. The initial dose was 0.05 mg/kg/min and was adjusted based on heart rate (HR) (target HR: 70 bpm < HR < 100 bpm within 72 hours). Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.
其他名称：
|
|
假比较器：control group
Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.
|
Control group also received natural saline via a micro pump,
|
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
The survival time of patients more than 28 days is defined as survival. The survival time of patients less than 28 days is defined as death.
大体时间：28 days
|
28 days
|
合作者和调查者
调查人员
- 研究主任：Rongguo Yu, MD、Fujian Provincial Hospital
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- K2010-001-01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
IPD 计划说明
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.